Study of Pedi-cRIB for Relapsed B-Cell Leukemia in Children and Young Adults
This study is looking at a new treatment combination for children and young adults (ages 1 to 25) with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatment. The treatment combines cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) with chemotherapy delivered into the spine (intrathecal methotrexate, hydrocortisone, cytarabine) and a compressed regimen of rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB). Researchers want to see how well this combination controls the leukemia and how safe it is. You might be able to join if you have B-ALL with at least 5% leukemia cells in your bone marrow that show specific markers (CD19 and CD22), and if you can't receive certain other treatments or have had issues with PEG-asparaginase.
- Study design
- This is an interventional study with a planned enrollment of 27 participants. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05645718
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Recruiting
PHASE2Ages 1–25InterventionalTreatmentM.D. Anderson Cancer CenterInvestigator-initiated
~27 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:CyclophosphamideVincristineBlinatumomabMethotrexateCytarabineMercaptopurine
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over through study completion; an average of 1 year.
Conditions
NCT05645718
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
M D Anderson Cancer Center
Houston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- David McCall, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Pediatric, adolescent, or young adult patients with B-ALL as per NCCN v2.2021 and WHO classification in relapse or primary refractory and, either/both of the following: • Unable to receive anthracyclines (see section 3.1.8) or is PEG-asparaginase intolerant.
For leukemia: Patients must have ≥ 5% blasts expressing CD19 and CD22 in the bone marrow as assessed by morphology or flow cytometry. However, if an adequate bone marrow sample cannot be obtained, patients may be enrolled if there is unequivocal evidence of leukemia with ≥ 5% blasts in the peripheral blood.
If patient does not have CD20, they can still be enrolled but will not receive rituximab.
Performance status: Lansky ≥ 50 for patients who are ≤ 16 years old and Karnofsky ≥ 50% for patients who are \> 16 years old.
Patients with asymptomatic CNS leukemia are eligible (see also Exclusion Criterion 3.2.2.)
Age \> = 1 years of age and less than 25 years of age.
The following baseline laboratory data:
Total serum bilirubin ≤1.5x upper limit of normal (ULN). Patients with known Gilbert's syndrome may have a total bilirubin up to ≤3 x ULN.
Adequate renal function per age51 unless related to the disease. Estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2 based on local institutional practice for age-appropriate determination (eg, Schwartz formula for pediatric patients or Cockcroft Gault formula for adults).
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤3 x ULN; ≤5 x ULN in case of suspected leukemic liver involvement
Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception methods during the study and 30 days after the last treatment and 8 months after the last dose of inotuzumab and 12 months after the last dose of rituximab. Effective methods of birth control include:
Birth control pills, shots, implants (placed under the skin by a health care provider) or patches (placed on the skin)
Intrauterine devices (IUDs)
Condom or occlusive cap (diaphragm or cervical/vault caps) used with Spermicide
Abstinence
Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment and 5 months after the last dose of inotuzumab.
Exclusion
Past or current history of a secondary or other primary tumor or a chronic myeloid leukemia (CML) blast crisis with exception of:
Curatively treated non-melanomatous skin cancer
Other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years
Presence of clinically significant uncontrolled CNS pathology such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, organic brain syndrome, or psychosis. Presence of the following are allowed: headaches, vomiting, nerve palsy
Medical history of cardiovascular disease such as:
Patients with uncontrolled, active infections (viral, bacterial, or fungal). Infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines are acceptable.
Known active hepatitis B or C infection or known seropositivity for HIV.
Patients with liver cirrhosis or other serious active liver disease or with suspected active alcohol abuse.
Active acute/chronic Graft-versus-Host Disease (GvHD) requiring systemic treatment; or receiving immunosuppression for GvHD prophylaxis within 2 weeks from the start of study therapy.
If patient has not recovered (as deemed by the investigator) from previous chemotherapy, surgery, radiation before the start of study drugs.
Females who are pregnant or lactating.
Male or female subjects of childbearing potential, unwilling to use an approved, effective means of contraception in accordance with institution's standards.
Other severe, uncontrolled acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated Protocol 2022-0312 V3 Dated 11/9/2023 Property of Leukemia at MD Anderson 17 with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the patient inappropriate for enrollment into this study.
Patients with Trisomy 21, or bone marrow failure syndromes are not eligible.
Prior history of allergic reaction to any of the agents.
Patients who are unable or unwilling to comply with all study requirements for clinical visits, examinations, tests, and procedures.
Patients may be excluded if they are currently enrolled in another ongoing clinical trial with investigational products
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year.